| Identification | Back Directory | [Name]
2-[4-[3-[(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-N,N-dimethylacetamide | [CAS]
1360550-04-4 | [Synonyms]
BI-665915)
BI 665915
(BI665915
2-[4-[3-[(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-N,N-dimethylacetamide
1H-Pyrazole-1-acetamide, 4-[3-[(1R)-1-[4-(2-amino-5-pyrimidinyl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]-N,N-dimethyl- | [Molecular Formula]
C24H26N8O2 | [MOL File]
1360550-04-4.mol | [Molecular Weight]
458.52 |
| Hazard Information | Back Directory | [Description]
BI-665915 is a 5-lipoxygenase activating protein inhibitor. | [Uses]
BI 665915 is an orally active and potent 5-lipoxygenase-activating protein (FLAP) inhibitor. BI 665915 inhibits FLAP production that blocks LTB4 biosynthesis in mice. BI 665915 is promising for research of various inflammatory diseases, including respiratory and cardiovascular diseases[1]. | [References]
[1] Takahashi H, et al. Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(R)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1, 2, 4] oxadiazol-5-yl)-pyrazol-1-yl]-N, N-dimethyl-acetamide (BI 665915)[J]. Journal of Medicinal Chemistry, 2015, 58(4): 1669-1690. |
|
|